New data from the Daybreak trial shows that Zeposia (ozanimod), a treatment for relapsing forms of multiple sclerosis, effectively reduced brain volume loss in patients for up to five years. The study also demonstrated a declining incidence of treatment-related adverse events over an extended period, suggesting a favorable safety profile for the drug.
A federal judge in New Jersey has rejected legal challenges to the Biden administration’s Medicare drug price negotiations from Johnson & Johnson and Bristol Myers Squibb. The ruling is a significant victory for the administration, as it strengthens the constitutionality of the program and weakens the pharmaceutical industry’s strategy of seeking varying decisions in lower courts. The ruling will allow the government to negotiate lower drug prices for seniors under the Inflation Reduction Act, potentially impacting drugmakers’ profits.
